Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe revision label has been updated from Revision: v3.5.3 to Revision: v3.5.4. This reflects a newer revision of the document in the revision history.SummaryDifference0.0%

- Check15 days agoChange DetectedTaoyuan District, Taiwan, 333 was removed and Taoyuan, Taiwan, 333 was added in the Locations section, reflecting a corrected city designation for the recruitment site.SummaryDifference0.0%

- Check23 days agoChange DetectedThe page's revision label has been updated from v3.5.2 to v3.5.3. This reflects a minor update to the page's metadata or documentation.SummaryDifference0.0%

- Check37 days agoChange DetectedAdded revision note: v3.5.2; removed revision: v3.5.0.SummaryDifference0.0%

- Check44 days agoChange Detected- Padua, Italy, 35128 was replaced by Padova, Italy, 35128 in the locations list.SummaryDifference0.0%

- Check66 days agoChange DetectedAdded the disease term Hepatocellular carcinoma and a Resources section linking to the Genetic and Rare Diseases Information Center. Updated the page revision from v3.4.3 to v3.5.0.SummaryDifference0.1%

Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.